IN192160B - - Google Patents

Info

Publication number
IN192160B
IN192160B IN651DE2000A IN192160B IN 192160 B IN192160 B IN 192160B IN 651DE2000 A IN651DE2000 A IN 651DE2000A IN 192160 B IN192160 B IN 192160B
Authority
IN
India
Prior art keywords
loratadine
particle size
surface area
dosage form
oral dosage
Prior art date
Application number
Other languages
English (en)
Inventor
Pananchukunath Manoj Kumar
Densheet Gupta
Rajiv Malik
Original Assignee
Ranbaxy Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11097068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN192160(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Lab filed Critical Ranbaxy Lab
Priority to IN651DE2000 priority Critical patent/IN192160B/en
Priority to EP01940893A priority patent/EP1303276B1/en
Priority to PT01940893T priority patent/PT1303276E/pt
Priority to ES01940893T priority patent/ES2230325T3/es
Priority to AT01940893T priority patent/ATE278404T1/de
Priority to DK01940893T priority patent/DK1303276T3/da
Priority to AU2001274381A priority patent/AU2001274381A1/en
Priority to PCT/IB2001/001098 priority patent/WO2002005816A1/en
Priority to BR0112597-4A priority patent/BR0112597A/pt
Priority to DE60106266T priority patent/DE60106266T2/de
Priority to HK03107616.6A priority patent/HK1055256B/en
Priority to US09/888,268 priority patent/US20020035119A1/en
Priority to ZA200300439A priority patent/ZA200300439B/en
Publication of IN192160B publication Critical patent/IN192160B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN651DE2000 2000-07-17 2000-07-17 IN192160B (cs)

Priority Applications (13)

Application Number Priority Date Filing Date Title
IN651DE2000 IN192160B (cs) 2000-07-17 2000-07-17
HK03107616.6A HK1055256B (en) 2000-07-17 2001-06-21 A bioavailable dosage form of loratadine
AU2001274381A AU2001274381A1 (en) 2000-07-17 2001-06-21 A bioavailable dosage form of loratadine
PT01940893T PT1303276E (pt) 2000-07-17 2001-06-21 Forma de dosagem biodisponivel de loratadina
ES01940893T ES2230325T3 (es) 2000-07-17 2001-06-21 Doificacion oral bio-aprovechable de loratadine.
AT01940893T ATE278404T1 (de) 2000-07-17 2001-06-21 Bioverfügbare darreichungsform von loratadin
DK01940893T DK1303276T3 (da) 2000-07-17 2001-06-21 Biotilgængelig doseringsform af loratadin
EP01940893A EP1303276B1 (en) 2000-07-17 2001-06-21 A bioavailable dosage form of loratadine
PCT/IB2001/001098 WO2002005816A1 (en) 2000-07-17 2001-06-21 A bioavailable dosage form of loratadine
BR0112597-4A BR0112597A (pt) 2000-07-17 2001-06-21 Forma biodisponìvel de dosagem de loratadina
DE60106266T DE60106266T2 (de) 2000-07-17 2001-06-21 Bioverfügbare darreichungsform von loratadin
US09/888,268 US20020035119A1 (en) 2000-07-17 2001-06-22 Bioavailable dosage form of loratadine
ZA200300439A ZA200300439B (en) 2000-07-17 2003-01-16 A bioavailable dosage form of loratadine.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN651DE2000 IN192160B (cs) 2000-07-17 2000-07-17

Publications (1)

Publication Number Publication Date
IN192160B true IN192160B (cs) 2004-02-28

Family

ID=11097068

Family Applications (1)

Application Number Title Priority Date Filing Date
IN651DE2000 IN192160B (cs) 2000-07-17 2000-07-17

Country Status (12)

Country Link
US (1) US20020035119A1 (cs)
EP (1) EP1303276B1 (cs)
AT (1) ATE278404T1 (cs)
AU (1) AU2001274381A1 (cs)
BR (1) BR0112597A (cs)
DE (1) DE60106266T2 (cs)
DK (1) DK1303276T3 (cs)
ES (1) ES2230325T3 (cs)
IN (1) IN192160B (cs)
PT (1) PT1303276E (cs)
WO (1) WO2002005816A1 (cs)
ZA (1) ZA200300439B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1635847B1 (en) 2003-06-13 2019-07-31 IDH Holding ApS Treatment of symptoms associated with bacterial vaginosis
JP3881640B2 (ja) * 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
EP1951197A4 (en) * 2005-11-10 2011-12-21 Alphapharm Pty Ltd METHOD OF CHECKING THE PARTICLE SIZE
US20100104636A1 (en) * 2006-12-21 2010-04-29 Panagiotis Keramidas Pharmaceutical Compound and Composition
EP2318350A4 (en) * 2008-07-25 2012-11-28 Alphapharm Pty Ltd ATOVAQUONE WITH PARTICLE DIAMETER (D90) VARIANT FROM MORE THAN 3 muM TO ABOUT 10 muM

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980778A (en) * 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
IL131317A (en) * 1999-08-09 2006-08-01 Cts Chemical Ind Ltd Binder for pharmaceutical compositions

Also Published As

Publication number Publication date
EP1303276B1 (en) 2004-10-06
ATE278404T1 (de) 2004-10-15
PT1303276E (pt) 2005-02-28
DE60106266D1 (de) 2004-11-11
DK1303276T3 (da) 2005-02-07
ES2230325T3 (es) 2005-05-01
EP1303276A1 (en) 2003-04-23
AU2001274381A1 (en) 2002-01-30
US20020035119A1 (en) 2002-03-21
DE60106266T2 (de) 2006-02-23
WO2002005816A1 (en) 2002-01-24
BR0112597A (pt) 2003-08-12
ZA200300439B (en) 2004-02-10
HK1055256A1 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
EG23943A (en) Flash-melt oral dosage formulation
HUP0203204A3 (en) Oral dosage forms
PL364621A1 (en) Nicotine-containing oral dosage form
AU7616001A (en) Probiotic recolonisation therapy
IL138471A0 (en) Novel semiconductor materials and their uses
GB9929613D0 (en) Manufacture of semiconductor material and devices using that material
IL154404A0 (en) Oral solid dose vaccine
AU9272401A (en) Cripto mutant and uses thereof
AU2001250032A1 (en) Oral care device
AU2002301259A1 (en) Simethicone solid oral dosage form
AU2001289521A1 (en) Biologically active oral preparation that can be site-specific released in colon
CA2388671A1 (en) Magnetic therapeutic mouth piece
AU2001259693A1 (en) Oral devices
HUP0500638A3 (en) Flashmelt oral dosage formulation
IN192160B (cs)
GB0130923D0 (en) Semiconductor device manufacture and design
GB0023654D0 (en) Device for administering doses of particulate material
HUP0401599A3 (en) Extended release oral dosage form
HUP0301433A3 (en) Use of antiprogestins for producung pharmaceutical compositions for induction of apoptosis in a cell
GB0011080D0 (en) Electrodes and plasma generating devices including electrodes
GB0014497D0 (en) Oral dosage form
GB0030587D0 (en) Oral administration of beneficial substances
IL149461A0 (en) Semiconductor nanocrystalline materials and their uses
PL341178A1 (en) Oral pharmaceutical dosage forms
IL160195A0 (en) Oral dosage form comprising a therapeutic agent and an adverse-effect agent